



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FLXN

Last Trade:	24.17
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	-0.34 (-1.387%)
Day Range	23.83 - 24.75
52-Week Range	15.44 - 29.41
Volume	420,377

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late stage development for moderate to severe osteoarthritis pain.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 10, 2017

[Flexion Therapeutics to Hold Investor & Analyst Day Today](#)

Jul 3, 2017

[Flexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017](#)

Jun 28, 2017

[Flexion Therapeutics Announces Appointment of Mark Levine as General Counsel](#)

Jun 23, 2017

[Flexion Therapeutics Named One of Boston Business Journal's Best Places to Work](#)

Jun 10, 2017

[Flexion Therapeutics to Present Data on Zilretta™ \(FX006\) at the American Diabetes Association's 77th Scientific Sessions](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 10, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 3, 2016

[Quarterly Report \(10-Q\)](#)